title: The impact of frailty status on survival after transcatheter aortic valve replacement in older adults with severe aortic stenosis: a single-center experience.
abstract: OBJECTIVE
  This study sought to evaluate the impact of frailty in older adults undergoing transcatheter aortic valve replacement (TAVR) for symptomatic aortic stenosis.
  
  
  BACKGROUND
  Frailty status impacts prognosis in older adults with heart disease; however, the impact of frailty on prognosis after TAVR is unknown.
  
  
  METHODS
  Gait speed, grip strength, serum albumin, and activities of daily living status were collected at baseline and used to derive a frailty score among patients who underwent TAVR procedures at a single large-volume institution. The cohort was dichotomized on the basis of median frailty score into frail and not frail groups. The impact of frailty on procedural outcomes (stroke, bleeding, vascular complications, acute kidney injury, and mortality at 30 days) and 1-year mortality was evaluated.
  
  
  RESULTS
  Frailty status was assessed in 159 subjects who underwent TAVR (age 86 ± 8 years, Society of Thoracic Surgery Risk Score 12 ± 4). Baseline frailty score was not associated with conventionally ascertained clinical variables or Society of Thoracic Surgery score. Although high frailty score was associated with a longer post-TAVR hospital stay when compared with lower frailty score (9 ± 6 days vs. 6 ± 5 days, respectively, p = 0.004), there were no significant crude associations between frailty status and procedural outcomes, suggesting adequacy of the standard selection process for identifying patients at risk for periprocedural complications after TAVR. Frailty status was independently associated with increased 1-year mortality (hazard ratio: 3.5, 95% confidence interval: 1.4 to 8.5, p = 0.007) after TAVR.
  
  
  CONCLUSIONS
  Frailty was not associated with increased periprocedural complications in patients selected as candidates to undergo TAVR but was associated with increased 1-year mortality after TAVR. Further studies will evaluate the independent value of this frailty composite in older adults with aortic stenosis.
authors.affiliation: Department of Medicine, Columbia University Medical Center, New York, New York 10032, USA.
authors.forename: Philip
authors.initials: P
authors.lastname: Green
authors.forename: Abigail E
authors.initials: AE
authors.lastname: Woglom
authors.forename: Philippe
authors.initials: P
authors.lastname: Genereux
authors.forename: Benoit
authors.initials: B
authors.lastname: Daneault
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Paradis
authors.forename: Susan
authors.initials: S
authors.lastname: Schnell
authors.forename: Marian
authors.initials: M
authors.lastname: Hawkey
authors.forename: Mathew S
authors.initials: MS
authors.lastname: Maurer
authors.forename: Ajay J
authors.initials: AJ
authors.lastname: Kirtane
authors.forename: Susheel
authors.initials: S
authors.lastname: Kodali
authors.forename: Jeffrey W
authors.initials: JW
authors.lastname: Moses
authors.forename: Martin B
authors.initials: MB
authors.lastname: Leon
authors.forename: Craig R
authors.initials: CR
authors.lastname: Smith
authors.forename: Mathew
authors.initials: M
authors.lastname: Williams
mesh_terms: D000203:Activities of Daily Living; D058186:Acute Kidney Injury / Q000209:etiology; D000368:Aged; D000369:Aged, 80 and over; D001024:Aortic Valve Stenosis / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D015415:Biomarkers / Q000097:blood; D006328:Cardiac Catheterization / Q000009:adverse effects* / Q000401:mortality; D016009:Chi-Square Distribution; D015897:Comorbidity; D005260:Female; D016330:Frail Elderly; D005684:Gait; D015577:Geriatric Assessment; D018737:Hand Strength; D019918:Heart Valve Prosthesis Implantation / Q000009:adverse effects* / Q000379:methods / Q000401:mortality; D006470:Hemorrhage / Q000209:etiology; D017052:Hospital Mortality; D061847:Hospitals, High-Volume; D006801:Humans; D053208:Kaplan-Meier Estimate; D007902:Length of Stay; D008297:Male; D009519:New York City; D016016:Proportional Hazards Models; D011446:Prospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D012709:Serum Albumin / Q000032:analysis; D012720:Severity of Illness Index; D020521:Stroke / Q000209:etiology; D013997:Time Factors; D016896:Treatment Outcome; D014652:Vascular Diseases / Q000209:etiology
chemical_list: D015415:Biomarkers; D012709:Serum Albumin